The essential roles of adiponectin and its receptors in regulating insulin resistance and lipid metabolism have been well discussed20,27,45, and our observation demonstrated that the adiponectin-based peptide agonist JT003 could reduce liver steatosis in mouse models of NAFLD and NASH. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.